Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1203||SWOG||A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NCIC-MA.27||NCIC CTG||A Randomized Phase III Trial of Exemestane Versus Anastrozole in PostMenopausal Women With Receptor Positive Primary Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|A021806||Alliance||A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0106||SWOG||A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-90601||CALGB||A Randomized Double-Blinded Phase III Study Comparing Gemcitabine; Cisplatin; and Bevacizumab to Gemcitabine; Cisplatin; and Placebo in Patients with Advanced Transitional Cell Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0262||GOG||GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865; IND #113912) in the Treatment of Primary Stage II; III OR IV Epithelial Ovarian; Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY001||NRG||A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent; Clear Cell Carcinoma of the Ovary; Fallopian Tube; or Peritoneum||Adult CIRB - Late Phase Emphasis||Completed|
|A081801||Alliance||Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5163||ECOG-ACRIN||INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0518||SWOG||Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced; Poor Prognosis Carcinoid Patients||Adult CIRB - Late Phase Emphasis||Completed|